All News Nevro Corp.

Equities

NVRO

US64157F1030

Real-time Estimate Cboe BZX Other stock markets 01:14:58 2024-05-14 pm EDT			5-day change	1st Jan Change
10.1 ^USD	-0.88%		-11.62%	-52.65%

May. 08	Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained	MT
May. 08	Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nevro to Present at BofA Securities 2024 Healthcare Conference	May. 09	PR
Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained	May. 08	MT
Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating	May. 08	MT
Wells Fargo Trims Nevro Price Target to $13 From $14, Maintains Equal Weight Rating	May. 08	MT
Nevro Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Nevro : First Quarter 2024 Earnings Presentation	May. 07	PU
Transcript : Nevro Corp., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (NVRO) NEVRO Reports Q1 Revenue $87M, vs. Street Est of $97.9M	May. 07	MT
Nevro: Q1 Earnings Snapshot	May. 07	AQ
Nevro Reports First-Quarter 2024 Financial Results	May. 07	PR
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024	May. 07	CI
Nevro Corp. Announces Resignation of Richard B. Carter as Chief Accounting Officer and Principal Accounting Officer, Effective May 10, 2024	Apr. 25	CI
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024	Apr. 17	PR
RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	Apr. 15	MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	Apr. 11	MT
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	Apr. 09	AQ
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating	Apr. 03	MT
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw	Feb. 28	PR
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says	Feb. 22	MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating	Feb. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Nevro Corp.

Equities

NVRO

US64157F1030

All News

Filters